<p>Syndax Pharmaceuticals (SNDX) 在交易者的雷达上再次引起关注，因为它在奥兰多的高端 ASH 血液学会议上展示了其 FDA 批准的癌症药物 Revuforj 和 Niktimvo 的新数据。</p>
<p>查看我们对 Syndax Pharmaceuticals 的最新分析。</p>
<p>围绕这些 ASH 更新的势头与股票的强劲表现相一致，Syndax 的股价年初至今回报约为 44%，过去一年总股东回报为 59%，尽管多年的总股东回报仍然为负。</p>
<p>如果这种事件驱动的走势让你想知道还有什么其他潜在的上涨机会，探索医疗保健股票可能是你下一个研究的方向。</p>
<p>尽管收入增长加速且有两款新药获批，Syndax 的股票仍以大幅折扣交易于华尔街目标价之下，投资者现在面临一个关键问题：Syndax 是被低估了，还是已经反映了未来的增长？</p>
<h2>最受欢迎的叙述：48.2% 被低估</h2>
<p>Syndax 最近收盘价为 20.37 美元，而叙述的公允价值约为 39 美元，这一估值故事明显倾向于上涨，值得更仔细的审视。</p>
<p><em>固定的运营费用基础，加上来自两个业务的产品销售和现金流的增长，预计将推动显著的运营杠杆，提升净利润率，加速盈利的路径。晚期管线的进展（包括前线试验、生命周期管理以及向 Niktimvo 的新适应症如 IPF 的扩展），结合强劲的临床数据和在精准肿瘤学中的市场领先地位，提供了与对创新、靶向疗法需求激增相一致的强劲长期增长途径，支持持续的多年度盈利势头。</em></p>
<p>阅读完整叙述。</p>
<p>想看看快速的收入扩张、利润率变化和丰富的未来收益倍数如何结合成这一上涨案例吗？叙述详细拆解了这一估值背后的每一个假设。</p>
<p><strong>结果：公允价值为 39.31 美元（被低估）</strong></p>
<p>完整阅读叙述，了解预测背后的原因。</p>
<p>然而，这一上涨案例仍然依赖于成功的标签扩展和持续的 Revuforj 使用，因为监管延迟或安全驱动的处方犹豫可能会破坏预期。</p>
<p>了解 Syndax Pharmaceuticals 叙述的关键风险。</p>
<h2>另一种观点：销售丰厚，故事便宜</h2>
<p>将这一乐观叙述与更简单的市销率视角叠加，呈现出更严峻的图景。SNDX 的市销率约为 15.9 倍，远高于美国生物技术同行的平均水平 12.3 倍和接近 1.3 倍的公允比率。这种差距表明，如果市场情绪降温，存在真正的估值风险。</p>
<p>查看数字对这一价格的看法——在我们的估值分析中了解更多。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55fa61da-ae1f-4d19-814f-da38552d6ebf/chart/ps-multiple-vs-industry?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55fa61da-ae1f-4d19-814f-da38552d6ebf/chart/ps-multiple-vs-industry"/></p>
<p>NasdaqGS:SNDX 截至 2025 年 12 月的市销率</p>
<h2>构建你自己的 Syndax Pharmaceuticals 叙述</h2>
<p>如果你认为故事的发展不同，或者更喜欢从数字中构建自己的观点，你可以在几分钟内自定义叙述，按照你的方式进行。</p>
<p>一个好的起点是我们的分析，强调投资者对 Syndax Pharmaceuticals 的两个关键回报的乐观预期。</p>
<h2>准备好进行下一个投资动作了吗？</h2>
<p>在你登出之前，通过扫描 Simply Wall Street 筛选器上的新机会来锁定你的优势，以免错过下一个突破。</p>
<ul>
<li>通过针对这些 913 只基于现金流的被低估股票，寻找定价错误的潜力，这些股票结合了你认为有吸引力的稳健基本面和现金流特征。</li>
<li>通过关注这 26 只参与现实世界人工智能应用的 AI 便士股票，探索科技主题。</li>
<li>通过确定这些 13 只收益率超过 3% 的股息股票，审查你的收入策略，这些股票提供可靠的、超出平均水平的分红，符合你的目标。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章不应被视为财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<p>移动基础设施用于国防和灾难</p>
<p>下一波机器人技术不是人形的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，任何地方。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>由 CiTech 赞助</p>

Syndax制药

<p>Syndax 制药（SNDX）在 ASH 会议上展示了其癌症药物的新数据后，正受到关注。尽管股票表现强劲，但与华尔街目标相比，股价被低估。公司在产品销售和临床进展方面显示出增长潜力。然而，由于高市销率，估值风险仍然存在。投资者被鼓励探索医疗保健股票以寻求潜在的上涨空间。该分析为一般性分析，不构成财务建议</p>

<p>Syndax Pharmaceuticals (SNDX) is back on traders radar after showcasing fresh data on its FDA approved cancer drugs Revuforj and Niktimvo at the high profile ASH hematology meeting in Orlando.</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals (SNDX) 在交易者的雷达上再次引起关注，因为它在奥兰多的高端 ASH 血液学会议上展示了其 FDA 批准的癌症药物 Revuforj 和 Niktimvo 的新数据。</p>
</div><p>See our latest analysis for Syndax Pharmaceuticals.</p>
<div class="lb-trans"><p>查看我们对 Syndax Pharmaceuticals 的最新分析。</p>
</div><p>The momentum around these ASH updates lines up with a strong run in the stock, with Syndax delivering a roughly 44% year to date share price return and a 59% total shareholder return over the last year, even as multi year total shareholder returns remain negative.</p>
<div class="lb-trans"><p>围绕这些 ASH 更新的势头与股票的强劲表现相一致，Syndax 的股价年初至今回报约为 44%，过去一年总股东回报为 59%，尽管多年的总股东回报仍然为负。</p>
</div><p>If this kind of event driven move has you wondering what else is setting up for potential upside, it could be worth exploring healthcare stocks as your next research stop.</p>
<div class="lb-trans"><p>如果这种事件驱动的走势让你想知道还有什么其他潜在的上涨机会，探索医疗保健股票可能是你下一个研究的方向。</p>
</div><p>With shares still trading at a steep discount to Wall Street targets despite accelerating revenue growth and two newly approved drugs, investors now face a pivotal question: Is Syndax undervalued or already pricing in its future growth?</p>
<div class="lb-trans"><p>尽管收入增长加速且有两款新药获批，Syndax 的股票仍以大幅折扣交易于华尔街目标价之下，投资者现在面临一个关键问题：Syndax 是被低估了，还是已经反映了未来的增长？</p>
</div><h2>Most Popular Narrative: 48.2% Undervalued</h2>
<div class="lb-trans"><h2>最受欢迎的叙述：48.2% 被低估</h2>
</div><p>With Syndax last closing at $20.37 against a narrative fair value of about $39, the valuation story leans aggressively toward upside and demands closer inspection.</p>
<div class="lb-trans"><p>Syndax 最近收盘价为 20.37 美元，而叙述的公允价值约为 39 美元，这一估值故事明显倾向于上涨，值得更仔细的审视。</p>
</div><p><em>Fixed operating expense base, together with expanding product sales and cash flow contributions from both franchises, is positioned to drive significant operating leverage, boosting net margins and accelerating the pathway to profitability. Late-stage pipeline advancements (including frontline trials, lifecycle management, and expansion into new indications like IPF for Niktimvo), coupled with strong clinical data and market-leading positions in precision oncology, provide robust long-term growth avenues aligned with surging demand for innovative, targeted therapies, supporting sustained multi-year earnings momentum.</em></p>
<div class="lb-trans"><p><em>固定的运营费用基础，加上来自两个业务的产品销售和现金流的增长，预计将推动显著的运营杠杆，提升净利润率，加速盈利的路径。晚期管线的进展（包括前线试验、生命周期管理以及向 Niktimvo 的新适应症如 IPF 的扩展），结合强劲的临床数据和在精准肿瘤学中的市场领先地位，提供了与对创新、靶向疗法需求激增相一致的强劲长期增长途径，支持持续的多年度盈利势头。</em></p>
</div><p>Read the complete narrative.</p>
<div class="lb-trans"><p>阅读完整叙述。</p>
</div><p>Want to see how rapid revenue expansion, shifting margins, and a rich future earnings multiple combine into that upside case? The narrative unpacks every assumption behind that valuation.</p>
<div class="lb-trans"><p>想看看快速的收入扩张、利润率变化和丰富的未来收益倍数如何结合成这一上涨案例吗？叙述详细拆解了这一估值背后的每一个假设。</p>
</div><p><strong>Result: Fair Value of $39.31 (UNDERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：公允价值为 39.31 美元（被低估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整阅读叙述，了解预测背后的原因。</p>
</div><p>However, this upside case still hinges on successful label expansions and sustained Revuforj uptake, as regulatory delays or safety driven prescribing hesitancy could derail expectations.</p>
<div class="lb-trans"><p>然而，这一上涨案例仍然依赖于成功的标签扩展和持续的 Revuforj 使用，因为监管延迟或安全驱动的处方犹豫可能会破坏预期。</p>
</div><p>Find out about the key risks to this Syndax Pharmaceuticals narrative.</p>
<div class="lb-trans"><p>了解 Syndax Pharmaceuticals 叙述的关键风险。</p>
</div><h2>Another View: Rich On Sales, Cheap On Story</h2>
<div class="lb-trans"><h2>另一种观点：销售丰厚，故事便宜</h2>
</div><p>Overlaying this upbeat narrative with a simpler price to sales lens paints a tougher picture. SNDX trades at about 15.9 times sales, well above the US biotech peer average of 12.3 times and a fair ratio closer to 1.3 times. That kind of gap suggests real valuation risk if sentiment cools.</p>
<div class="lb-trans"><p>将这一乐观叙述与更简单的市销率视角叠加，呈现出更严峻的图景。SNDX 的市销率约为 15.9 倍，远高于美国生物技术同行的平均水平 12.3 倍和接近 1.3 倍的公允比率。这种差距表明，如果市场情绪降温，存在真正的估值风险。</p>
</div><p>See what the numbers say about this price — find out in our valuation breakdown.</p>
<div class="lb-trans"><p>查看数字对这一价格的看法——在我们的估值分析中了解更多。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55fa61da-ae1f-4d19-814f-da38552d6ebf/chart/ps-multiple-vs-industry" alt="" original-src="https://images.simplywall.st/company/55fa61da-ae1f-4d19-814f-da38552d6ebf/chart/ps-multiple-vs-industry"/></p>
<p>NasdaqGS:SNDX PS Ratio as at Dec 2025</p>
<div class="lb-trans"><p>NasdaqGS:SNDX 截至 2025 年 12 月的市销率</p>
</div><h2>Build Your Own Syndax Pharmaceuticals Narrative</h2>
<div class="lb-trans"><h2>构建你自己的 Syndax Pharmaceuticals 叙述</h2>
</div><p>If you see the story playing out differently or prefer building your own view from the numbers, you can craft a custom narrative in minutes, Do it your way.</p>
<div class="lb-trans"><p>如果你认为故事的发展不同，或者更喜欢从数字中构建自己的观点，你可以在几分钟内自定义叙述，按照你的方式进行。</p>
</div><p>A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding Syndax Pharmaceuticals.</p>
<div class="lb-trans"><p>一个好的起点是我们的分析，强调投资者对 Syndax Pharmaceuticals 的两个关键回报的乐观预期。</p>
</div><h2>Ready for your next investment move?</h2>
<div class="lb-trans"><h2>准备好进行下一个投资动作了吗？</h2>
</div><p>Before you log off, lock in your edge by scanning fresh opportunities on the Simply Wall Street Screener so you are not late to the next breakout.</p>
<div class="lb-trans"><p>在你登出之前，通过扫描 Simply Wall Street 筛选器上的新机会来锁定你的优势，以免错过下一个突破。</p>
</div><ul>
<li>Look for mispriced potential by targeting these 913 undervalued stocks based on cash flows that combine solid fundamentals with cash flow profiles you find attractive.</li>
<li>Explore the technology theme by focusing on these 26 AI penny stocks that are involved in real world artificial intelligence applications.</li>
<li>Review your income strategy by pinpointing these 13 dividend stocks with yields &gt; 3% that offer reliable, above average payouts consistent with your goals.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过针对这些 913 只基于现金流的被低估股票，寻找定价错误的潜力，这些股票结合了你认为有吸引力的稳健基本面和现金流特征。</li>
<li>通过关注这 26 只参与现实世界人工智能应用的 AI 便士股票，探索科技主题。</li>
<li>通过确定这些 13 只收益率超过 3% 的股息股票，审查你的收入策略，这些股票提供可靠的、超出平均水平的分红，符合你的目标。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章不应被视为财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>移动基础设施用于国防和灾难</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是人形的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，任何地方。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 赞助</p>
</div>

Syndax 制药（SNDX）：在关键 ASH 数据发布后对 Revuforj 和 Niktimvo 进行估值评估